Induction of tolerance in composite-tissue allografts

Area of Science:

• Immunology
• Transplantation Biology
• Regenerative Medicine

Background:

• Composite-tissue allograft (CTA) transplantation, like hand transplants, is clinically feasible but limited by risks of lifelong immunosuppression.
• Developing strategies to induce donor-specific tolerance is crucial for routine CTA clinical application.
• This study presents a novel method to achieve long-term tolerance without preconditioning or chronic immunosuppression.

Purpose of the Study:

• To develop and evaluate a novel protocol for inducing long-term, donor-specific tolerance to composite-tissue allografts.
• To eliminate the need for chronic immunosuppression in allograft recipients.
• To assess the efficacy of a combined immunomodulatory approach in a preclinical transplantation model.

Main Methods:

• A 35-day protocol was developed using cyclosporine A (CsA) and a mouse monoclonal antibody against rat alphabeta-T-cell receptor (TCR).
• The protocol was tested in a rat hindlimb transplantation model across a major histocompatibility complex (MHC) barrier.
• Efficacy was assessed using skin grafting, flow cytometry (FC), and mixed lymphocyte reaction (MLR) to confirm tolerance and chimerism.

Main Results:

• Long-term tolerance (>720 days) was achieved in all composite-tissue allograft recipients (n=5) without requiring further immunosuppression.
• Donor-specific tolerance was confirmed through in vivo skin grafting and in vitro mixed lymphocyte reactions.
• Recipients rejected third-party grafts, demonstrating retained immunocompetence.

Conclusions:

• A combined protocol of alphabeta-TCR monoclonal antibody and CsA effectively induces donor-specific tolerance across the MHC barrier in a CTA model.
• This approach successfully bypasses the need for recipient conditioning and chronic immunosuppression.
• These findings hold promise for advancing therapeutic strategies and expanding clinical applications of composite-tissue transplantation.